Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edesa Biotech (EDSA) Cash from Operations (2016 - 2022)

Edesa Biotech's Cash from Operations history spans 10 years, with the latest figure at 5628207.0 for Q3 2022.

  • For Q3 2022, Cash from Operations fell 1483.98% year-over-year to 5628207.0; the TTM value through Sep 2022 reached 12279302.0, up 10.14%, while the annual FY2025 figure was 7300000.0, 49.28% down from the prior year.
  • Cash from Operations for Q3 2022 was 5628207.0 at Edesa Biotech, down from 3026827.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 355321.0 in Q3 2021 and bottomed at 7179528.0 in Q1 2021.
  • The 5-year median for Cash from Operations is 1530671.0 (2018), against an average of 2282915.56.
  • The largest YoY upside for Cash from Operations was 94.2% in 2022 against a maximum downside of 1483.98% in 2022.
  • A 5-year view of Cash from Operations shows it stood at 382346.0 in 2018, then tumbled by 106.54% to 789712.0 in 2019, then plummeted by 281.22% to 3010529.0 in 2020, then decreased by 6.55% to 3207614.0 in 2021, then plummeted by 75.46% to 5628207.0 in 2022.
  • Per Business Quant, the three most recent readings for EDSA's Cash from Operations are 5628207.0 (Q3 2022), 3026827.0 (Q2 2022), and 416654.0 (Q1 2022).